-+ 0.00%
-+ 0.00%
-+ 0.00%

KAZIA THERAPEUTICS REPORTS PRECLINICAL DATA SHOWING PAXALISIB REPROGRAMS IMMUNOTHERAPY-RESISTANT MSS/PMMR COLORECTAL CANCER AND ENHANCES RESPONSE TO IMMUNOTHERAPY

Reuters·09/01/2026 11:30:02

Please log in to view news